Delivery Order SPE2DB22D1002-SPE2DB25FLFD3
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for RINVOQ ER 15 mg tablets (30-unit bottles) under a firm fixed-price contract valued at $10,362.56. This is a non-set-aside competitive award with an ultimate completion date of July 30, 2025. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle...
- The Defense Logistics Agency awarded a $28,416.82 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award carries no set-aside designation, reflecting the company's proven capability to...
- The Defense Logistics Agency awarded a delivery order valued at approximately $40.2K to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on September 3, 2025, with completion scheduled for September 4, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $1 billion through December 2026), which serves as a comprehensive pharmaceutical supply vehicle...
- The Defense Logistics Agency awarded a $18,669.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $26,154.99 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of RINVOQ ER 30 mg tablets (quantity: 30-unit bottles). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $11,859.53 to AmerisourceBergen Drug Corp on July 14, 2025, for RINVOQ ER 15 mg tablets (quantity: 30 units). This competitive award, using firm fixed price terms with no set-aside designation, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a $32,318.92 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a $80,832.18 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract involves no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $37,112.83 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-tablet units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price, non-set-aside delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract is being...
- The Defense Logistics Agency awarded a delivery order valued at $9,728.70 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order is issued under AmerisourceBergen's larger...
- SPE2DB22D1002Indefinite Delivery Contract
- SPE2DB22D1002-SPE2DB25FLFD3Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,244.04 to AmerisourceBergen Drug Corp on July 22, 2025, for RINVOQ ER 15 mg tablets (30-count unit dosages), with completion scheduled for July 23, 2025. This firm fixed-price, competitively awarded contract (no set-aside) is being performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999.00 prime vendor agreement valued through December 2026 that serves as the company's primary vehicle for supplying pharmaceutical products and medical supplies to military healthcare systems globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, maintains a substantial portfolio of federal medical procurement contracts with the Defense Logistics Agency and Defense Health Agency. The company's federal contracting demonstrates broad capability across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and vaccines. This specific delivery order for RINVOQ ER (upadacitinib extended-release), a immunosuppressant medication, reflects the company's role in supporting the military health system's pharmaceutical supply chain and its ability to fulfill targeted medical procurement requirements through established federal contract vehicles.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 7/22/25 |